title: Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
abstract: Peroxisome proliferator-activated receptor (PPAR)-gamma controls growth, differentiation, and inflammation. PPAR-gamma agonists exert anti-inflammatory effects in vitro and inhibit the activation of pancreas stellate cells, implicated in the formation and progression of fibrosis. We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis. Mice received six hourly intraperitoneal injections with 50 microg/kg of cerulein or saline, three times a week for 6 weeks. One week after the last injection all mice were sacrificed. Untreated mice were compared with mice treated with troglitazone either during weeks 1 to 6 or weeks 4 to 6. All mice that received cerulein injections displayed histopathological signs of chronic pancreatitis at week 7. Troglitazone treatment improved all markers for severity of pancreatitis. Moreover, early and postponed troglitazone treatments were equally effective in diminishing intrapancreatic fibrosis as quantified by Sirius red staining, hydroxyproline content, and laminin staining as well as the increased number of pancreatic stellate cells and pancreas levels of transforming growth factor-beta. Thus, troglitazone attenuated pancreatic damage and inflammation in experimental chronic pancreatitis and remained beneficial in a therapeutic setting when given after initial damage had been established.
authors.affiliation: Laboratory of Experimental Internal Medicine, University of Amsterdam, Amsterdam, The Netherlands. d.j.vanwesterloo@amc.uva.nl
authors.forename: David J
authors.initials: DJ
authors.lastname: van Westerloo
authors.forename: Sandrine
authors.initials: S
authors.lastname: Florquin
authors.forename: Anita M
authors.initials: AM
authors.lastname: de Boer
authors.forename: Joost
authors.initials: J
authors.lastname: Daalhuisen
authors.forename: Alex F
authors.initials: AF
authors.lastname: de Vos
authors.forename: Marco J
authors.initials: MJ
authors.lastname: Bruno
authors.forename: Tom
authors.initials: T
authors.lastname: van der Poll
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D002454:Cell Differentiation; D002108:Ceruletide / Q000494:pharmacology; D002839:Chromans / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D004195:Disease Models, Animal; D005355:Fibrosis; D007249:Inflammation; D015850:Interleukin-6 / Q000097:blood; D008024:Ligands; D051379:Mice; D008810:Mice, Inbred C57BL; D009130:Muscle, Smooth / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism; D010195:Pancreatitis / Q000188:drug therapy* / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000378:metabolism; D012965:Sodium Chloride / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D053773:Transforming Growth Factor beta1; D000077288:Troglitazone
chemical_list: D000199:Actins; D002839:Chromans; D015850:Interleukin-6; D008024:Ligands; D047495:PPAR gamma; D010975:Platelet Aggregation Inhibitors; D047888:Receptors, Tumor Necrosis Factor, Type I; C508961:Tgfb1 protein, mouse; D045162:Thiazolidinediones; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D012965:Sodium Chloride; D002108:Ceruletide; D003094:Collagen; D000077288:Troglitazone
references.citation: Am J Pathol. 1999 Nov;155(5):1749-58
references.pmid: 10550331
references.citation: Arch Biochem Biophys. 1961 May;93:440-7
references.pmid: 13786180
references.citation: Lab Invest. 2000 Jan;80(1):47-55
references.pmid: 10653002
references.citation: Baillieres Best Pract Res Clin Gastroenterol. 1999 Jul;13(2):265-89
references.pmid: 11030606
references.citation: Gastroenterology. 2001 Feb;120(3):682-707
references.pmid: 11179244
references.citation: Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G974-8
references.pmid: 11292607
references.citation: Kidney Int. 2001 May;59(5):1899-910
references.pmid: 11318962
references.citation: Toxicol Pathol. 2001 Mar-Apr;29(2):224-31
references.pmid: 11421489
references.citation: Gastroenterology. 2001 Sep;121(3):685-98
references.pmid: 11522753
references.citation: J Biol Chem. 2001 Dec 7;276(49):45888-94
references.pmid: 11590167
references.citation: J Biol Chem. 2002 Jan 4;277(1):141-7
references.pmid: 11606585
references.citation: Biochem Biophys Res Commun. 2002 Feb 15;291(1):55-61
references.pmid: 11829461
references.citation: Pancreas. 2002 Mar;24(2):184-90
references.pmid: 11854624
references.citation: Gastroenterology. 2002 May;122(5):1303-13
references.pmid: 11984517
references.citation: Gastroenterology. 2002 May;122(5):1525-8
references.pmid: 11984538
references.citation: Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1105-12
references.pmid: 12016137
references.citation: Gastroenterology. 2002 Jun;122(7):1924-40
references.pmid: 12055599
references.citation: Curr Opin Clin Nutr Metab Care. 2002 Sep;5(5):551-9
references.pmid: 12172480
references.citation: Ann Med. 2002;34(3):217-24
references.pmid: 12173692
references.citation: Int Immunopharmacol. 2002 Jul;2(8):1029-44
references.pmid: 12349941
references.citation: Adv Drug Deliv Rev. 2002 Nov 5;54(9):1173-97
references.pmid: 12393300
references.citation: Gastrointest Endosc. 2002 Dec;56(6 Suppl):S226-30
references.pmid: 12447272
references.citation: Am J Respir Crit Care Med. 2003 Jan 15;167(2):171-9
references.pmid: 12406830
references.citation: Gastroenterology. 2003 Feb;124(2):361-7
references.pmid: 12557142
references.citation: Pancreas. 2003 Apr;26(3):239-42
references.pmid: 12657949
references.citation: Gastroenterology. 2003 Apr;124(4):1010-9
references.pmid: 12671898
references.citation: Pancreas. 2003 Jul;27(1):58-66
references.pmid: 12826907
references.citation: Intensive Care Med. 2004 May;30(5):951-6
references.pmid: 14985957
references.citation: Crit Care Med. 2004 Oct;32(10):1997-2001
references.pmid: 15483406
references.citation: Lab Invest. 1993 Mar;68(3):296-307
references.pmid: 8383778
references.citation: Bone Miner. 1994 Nov;27(2):133-44
references.pmid: 7711521
references.citation: Gastroenterology. 1995 Jun;108(6):1873-81
references.pmid: 7768393
references.citation: Am J Pathol. 1995 Jul;147(1):42-52
references.pmid: 7604884
references.citation: Br J Surg. 1996 Mar;83(3):349-53
references.pmid: 8665189
references.citation: J Mol Cell Cardiol. 1997 Jan;29(1):247-53
references.pmid: 9040039
references.citation: Nature. 1998 Jan 1;391(6662):79-82
references.pmid: 9422508
references.citation: Gastroenterology. 1998 Aug;115(2):421-32
references.pmid: 9679048
references.citation: Inflamm Bowel Dis. 1998 Aug;4(3):187-95
references.pmid: 9741020
references.citation: Gut. 1999 Aug;45(2):269-77
references.pmid: 10403741
references.citation: Am J Pathol. 1999 Oct;155(4):1087-95
references.pmid: 10514391
references.citation: Hepatogastroenterology. 1999 Sep-Oct;46(29):2751-6
references.pmid: 10576340